Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the […]
Dr Lindsay Hall of the Quadram Institute talks to us about the preterm infant gut microbiota and its modulation.
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, announced that the Opposition Division of the European Patent Office has upheld Vedanta’s […]
This 5th Pharmabiotics Conference Edition, hosted by the Pharmabiotic Research Institute, took place Mid-March in Paris and peaked as the most successful to date, with over 190 delegates attending over the 2-day event. As in […]
Highlights Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by […]
This month’s 5-minute microbiome science roundup includes some important papers published this month related to both health and disease. The two colorectal cancer microbiome-related papers published in Nature are a sign that the field is beginning […]
The first patient participating in the combination phase I/II study of MRx0518 and *KEYTRUDA® in collaboration with Merck & Co., Inc., Kenilworth, NJ., USA and 4D’s strategic collaboration with MD Anderson has completed Cycle 1 […]
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Full-Spectrum Microbiota® (FSM®) therapy for the treatment of children […]
Why Phages, and Why Now? Many modern diseases have been linked to alterations in the microbiome and changing it back could be the key to restoring health. Bacteriophages (phages) are viruses that kill bacteria with […]
It is estimated that nearly 3 million newborns and 1.2 million children suffer from sepsis globally each year, with limited effective forms of prevention currently available. To help combat this, DuPont Nutrition & Biosciences (DuPont), […]
This interview was originally published on the Biofortis Mérieux NutriSciences’ Blog. Pr Nicola Segata (Centre for Integrative Biology (CIBIO), University of Trento, Italy) received a €10,000 award from Institut Mérieux, on March 13th at Pharmabiotics 2019 to support his research […]